Form 4: Amgen SVP Derek Miller Reports Stock and Option Transactions

Derek Miller, SVP of Human Resources at Amgen, reports the acquisition of restricted stock units and non-qualified stock options, along with dividend equivalents.

Summary

• Derek Miller, SVP of Human Resources at Amgen, filed a Form 4 detailing changes in beneficial ownership.
• On May 6, 2025, Miller acquired 961 Restricted Stock Units (RSUs) and 6,214 non-qualified stock options.
• The RSUs vest in four equal annual installments starting May 6, 2026, and will be paid in shares of Amgen's common stock on a one-to-one basis.
• The non-qualified stock options, with an exercise price of $270.44, also vest in four equal annual installments starting May 6, 2026.
• Miller also received 105 Dividend Equivalents (DEs) related to unvested RSUs, which will be paid out in shares of common stock according to the vesting schedule.
• Following the reported transactions, Miller beneficially owns 10,189 shares of Amgen common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it's a standard regulatory filing detailing stock and option grants. It doesn't inherently indicate positive or negative performance for the company.

Positives

• The grant of RSUs and stock options aligns Miller's interests with those of Amgen's shareholders.
• The vesting schedule encourages long-term commitment from Miller.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the RSUs and stock options.

Industry Context

This filing is a routine disclosure related to executive compensation and is typical for publicly traded companies like Amgen. It reflects standard practices for incentivizing key personnel.

Comparison to Industry Standards

• Equity grants such as RSUs and stock options are a common component of executive compensation packages in the biotechnology and pharmaceutical industries.
• Companies like Johnson & Johnson, Pfizer, and Merck also utilize similar equity-based compensation plans to align executive interests with shareholder value.
• The vesting schedules and terms of these grants are generally in line with industry norms, designed to retain and motivate key employees over the long term.

Stakeholder Impact

• Shareholders may view the equity grants as a way to incentivize management and align their interests with long-term company performance.
• Employees may see this as a positive sign of investment in key personnel.

Key Dates

Keywords

Form 4, Amgen, Derek Miller, RSU, Stock Options, Dividend Equivalents, Beneficial Ownership, Equity Incentive Plan